ThroLy score
The Thrombosis Lymphoma (ThroLy) predictive score is a multivariable model for assessing the probability of thromboembolic events in patients with lymphoma. (Multivariable models are those that incorporate multiple independent variables.)
Characteristics
The ThroLy score was developed and published in 2016 by a group of doctors from Serbia and the United States.[1] As a simple model, it was initially internally validated based on individual clinical and laboratory patient characteristics that identify lymphoma patients at risk for a thromboembolic event. Based on an investigation that was conducted on derivation and validation cohorts, it was determined that the variables independently associated with a risk of thromboembolism in lymphoma patients are: previous venous and/or arterial events; mediastinal involvement; a BMI greater than 30 kg/m2; reduced mobility; extra-nodal localization; neutropenia; and a hemoglobin level less than 100g/L.[1] [2]
| Patient characteristics | Assigned score |
|---|---|
| Previous venous thromboembolic event | 2 |
| Reduced mobility | 1 |
| Previous acute myocardial infarction or stroke | 2 |
| Obesity (BMI ≥ 30) | 2 |
| Extranodal localization | 1 |
| Mediastinal involvement | 2 |
| Neutropenia | 1 |
| Hemoglobin˂100g/L | 1 |
Risk classification
Based on the risk score, patients with lymphoma can be classified into three different risk groups. [2]
| Risk group | ThroLy score |
|---|---|
| Low risk | 0-1 |
| Intermediate risk | 2-3 |
| High risk | ≥4 |
Further validations
The ThroLy score considers some particular characteristics of lymphoma patients, such as extranodal localization and mediastinal involvement. In addition to having a strong positive predictive value, the score is not limited to either hospitalized or outpatient settings, and does not require non-routine laboratory analyses. The results of additional studies may be needed before it can be fully applicable in clinical practice; several validation studies have been performed, and several more are ongoing.[3][4][5]
References
- ^ a b Antic, Darko; Milic, Natasa; Nikolovski, Srdjan; Todorovic, Milena; Bila, Jelena; Djurdjevic, Predrag; Andjelic, Bosko; Djurasinovic, Vladislava; Sretenovic, Aleksandra; Vukovic, Vojin; Jelicic, Jelena (October 2016). "Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients: Multivariable Predictive Model". American Journal of Hematology. 91 (10): 1014–1019. doi:10.1002/ajh.24466. PMID 27380861. S2CID 1724916.
- ^ a b Abdel-Razeq, Hikmat; Ma’koseh, Mohammad; Mansour, Asem; Bater, Rayan; Amarin, Rula; Abufara, Alaa; Halahleh, Khalid; Manassra, Mohammad; Alrwashdeh, Mohammad; Almomani, Mohammad; Zmaily, Mais (January 2021). "The Application of the ThroLy Risk Assessment Model to Predict Venous Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma". Clinical and Applied Thrombosis/Hemostasis. 27: 107602962110459. doi:10.1177/10760296211045908. ISSN 1076-0296. PMC 8642105. PMID 34590497.
- ^ Rupa-Matysek, Joanna; Brzeźniakiewicz-Janus, Katarzyna; Gil, Lidia; Krasiński, Zbigniew; Komarnicki, Mieczysław (July 2018). "Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice". Cancer Medicine. 7 (7): 2868–2875. doi:10.1002/cam4.1540. PMC 6051175. PMID 29761831.
- ^ Antic, Darko; Milic, Natasa; Mihaljevic, Biljana; Cheson, Bruce; Narkhede, Mayur; Abdel-Razeq, Hikmat; Panovska, Irina; Trajkova, Sanja; Popova, Marija; Aurer, Igor; Boban, Ana (November 29, 2018). "External Validation and Revision of Thrombosis Lymphoma /Throly/ Score". Blood. 132 (Supplement 1): 140. doi:10.1182/blood-2018-99-115568. ISSN 0006-4971.
- ^ Assanto, Giovanni Manfredi; Salvatori, Martina; Pontecorvo, Sara; Maiorana, Gianluca; Cenfra, Natalia; D’elia, Gianna Maria; Bianchi, Maria Paola; Annechini, Giorgia; Santoro, Cristina Santoro; Martelli, Maurizio; Tafuri, Agostino; Pulsoni, Alessandro; Del Giudice, Ilaria; Chistolini, Antonio (August 2023). "S219: Predicting Thrombotic Risk in Patients with Hodgkin Lymphoma: A Multicentric Study of Throly and Khorana Risk Scores". HemaSphere. 7 (S3): e700140a. doi:10.1097/01.HS9.0000967788.70014.0a. ISSN 2572-9241. PMC 10428474.
